POXEL extends its financing horizon through the restructuring of its debt and the establishment of an equity financing line – 08/08/2022 at 07:00

To receive POXEL information in real time, send a request to [email protected]

POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, announces today (1) the signing of an agreement with IPF aimed at restructuring the existing debt and (2) setting up an equity financing line with IRIS for a maximum amount of 6 million euros. Based on these two agreements, the Company estimates that its resources will be sufficient to finance its operations and its investment needs at least until February 2023.

Source link -86